Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Innoviva Inc
INVA | US
23.57
USD0.09
0.38%
INVA | US
Loading StockChartView...
About Innoviva Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
23.57
Open
23.39
High
23.64
Low
23.01
Innoviva Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA a once-daily combination medicine consisting of a LABA vilanterol (VI) an inhaled corticosteroid (ICS) and fluticasone furoate; ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA VI; and TRELEGY ELLIPTA a once-daily combination medicine consisting of an ICS LAMA and LABA. Innoviva Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance Inc. and changed its name to Innoviva Inc. in January 2016. Innoviva Inc. was incorporated in 1996 and is headquartered in Burlingame California.
View LessINVA | US
Risk
22.7
Sharpe
0.82
Luna's Score
55/100
Recommendation
Hold
Luna says (INVA | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
21.6%1 month
22.7%3 months
26.0%6 months
30.1%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
11.32
Fwd. PE
-
Price to book
1.88
Debt to equity
0.68
Debt to assets
0.37
Ent. to EBITDA
7.40
Ent. to rev.
4.50
PEG
0.24
Other Fundamentals
EBITDA
199.53M
MarketCap
1.47B
MarketCap(USD)
1.47B
Div. yield
-
Op. margin
54.74
Erngs. growth
10.40
Rev. growth
23.30
Ret. on equity
23.83
Short ratio
20.38
Short perc.
36.84
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.44
Range1M
2.41
Range3M
5.72
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.67
Price X volume
10.15M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 7.40 | 0.53 | Expensive |
| Ent. to Revenue | 4.50 | 3,967.00 | Cheaper |
| PE Ratio | 11.32 | 41.03 | Cheaper |
| Price to Book | 1.88 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 26.03 | 72.80 | Lower Risk |
| Debt to Equity | 0.68 | -1.23 | Expensive |
| Debt to Assets | 0.37 | 0.25 | Expensive |
| Market Cap | 1.47B | 3.66B | Emerging |
